The Technical AnalystExchange: WSE Sector: Healthcare Industry: Biotechnology
Captor Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% PLN76.00
America/New_York / 17 mai 2024 @ 11:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 353.07 mill |
| EPS: | -15.19 |
| P/E: | -5.00 |
| Earnings Date: | May 27, 2024 |
| SharesOutstanding: | 4.65 mill |
| Avg Daily Volume: | 0.0029 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.00 | sector: PE 21.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.41x |
| Company: PE -5.00 | industry: PE 12.24 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
PLN 72.59 - 79.41 ( +/- 4.49%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | PLN76.00 (0.00% ) |
| Volume | 0.0004 mill |
| Avg. Vol. | 0.0029 mill |
| % of Avg. Vol | 15.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CTX.WA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CTX.WA
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.